The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.
Open accessAbstract
The immunoregulatory effects of transforming growth factor beta (TGF-beta) and recombinant murine tumor necrosis factor alpha (rMuTNF-alpha) on CTL generation and activity were examined. The results demonstrate that TGF-beta, in a dose-dependent manner, inhibited CTL generation but not CTL activity. The inhibitory effects were detected only when TGF-beta was added within the first 48 h of the MLC. Little activity was seen when it was added thereafter, including the addition of TGF-beta to the cytotoxicity assay. The production of TNF-alpha, which occurs during early phases of the MLC and which is inhibited in the presence of TGF-beta, appears to have an important regulatory role, as altering the levels of TNF-alpha in an MLC can significantly influence CTL development. The inhibitory effects of TGF-beta on the MLC can be significantly reversed by the addition of rMuTNF-alpha to the cultures. These results demonstrate that TGF-beta can inhibit MLC and subsequent CTL generation at early stages of the reaction, and such inhibition may involve the suppression of TNF-alpha production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin
Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., & Goeddel, D. V. (1984) · Nature · doi:10.1038/312724a0 · Cited by 1,736
Self-citationKehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,582
Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. A., & Shepard, H. M. (1985) · Science · doi:10.1126/science.3933111 · Cited by 1,580
Self-citationEspevik, T., & Nissen-Meyer, J. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90322-4 · Cited by 1,243
Self-citationTransforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
Kehrl, J. H., Roberts, A. B., Wakefield, L. M., Jakowlew, S., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.12.3855 · Cited by 759
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity
Gray, P. W., Aggarwal, B. B., Benton, C. V., Bringman, T. S., Henzel, W. J., Jarrett, J. A., Leung, D. W., Moffat, B., Ng, P., Svedersky, L. P., et al. (1984) · Nature · doi:10.1038/312721a0 · Cited by 640
Self-citationScheurich, P., Thoma, B., Ucer, U., & Pfizenmaier, K. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.6.1786 · Cited by 492
Nedwin, G. E., Svedersky, L. P., Bringman, T. S., Palladino, M. A., & Goeddel, D. V. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2492 · Cited by 485
Self-citationInhibition of cytokine production by cyclosporin A and transforming growth factor beta.
Espevik, T., Figari, I. S., Shalaby, M. R., Lackides, G. A., Lewis, G. D., Shepard, H. M., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.2.571 · Cited by 447
Self-citation
Cited by
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
Self-citationThe Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Peptide Growth Factors and Their Receptors I · doi:10.1007/978-1-4612-3210-0_8 · Cited by 861
Peptide growth factors are multifunctional
Sporn, M. B., & Roberts, A. B. (1988) · Nature · doi:10.1038/332217a0 · Cited by 818
Transforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792
Balkwill, F. R., & Burke, F. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90085-6 · Cited by 783
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1990) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-49295-2_8 · Cited by 746
Miller, A., Lider, O., Roberts, A. B., Sporn, M. B., & Weiner, H. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.421 · Cited by 732
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
Yamagiwa, S., Gray, J. D., Hashimoto, S., & Horwitz, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7282 · Cited by 538
TGF-β Family Signaling in Tumor Suppression and Cancer Progression
Seoane, J., & Gomis, R. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022277 · Cited by 510
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Anti—tumor necrosis factor therapy abrogates autoimmune demyelination
Selmaj, K., Raine, C. S., & Cross, A. H. (1991) · Annals of Neurology · doi:10.1002/ana.410300510 · Cited by 436
Transforming growth factor beta (TGF-?) in inflammation: A cause and a cure
Wahl, S. M. (1992) · Journal of Clinical Immunology · doi:10.1007/bf00918135 · Cited by 407
Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., & Rowley, D. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1486 · Cited by 403
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.
Kuruvilla, A. P., Shah, R., Hochwald, G. M., Liggitt, H. D., Palladino, M. A., & Thorbecke, G. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2918 · Cited by 399
Self-citationSahin, I. H., Akce, M., Alese, O., Shaib, W., Lesinski, G. B., El-Rayes, B., & Wu, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 393
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulation
Wan, Y. Y., & Flavell, R. A. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00565.x · Cited by 380
Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., & Palladino, M. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7375 · Cited by 360
Self-citationTwo Different Cell Types have Different Major Receptors for Human Tumor Necrosis Factor (TNFα)
Hohmann, H. P., Remy, R., Brockhaus, M., & van Loon, A. P. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63791-3 · Cited by 356
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 334
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., & Sobol, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2909 · Cited by 334
Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massague, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316
Macrophages and post-burn immune dysfunction
Schwacha, M. G. (2003) · Burns · doi:10.1016/s0305-4179(02)00187-0 · Cited by 310
Theiler's Virus Infection: a Model for Multiple Sclerosis
Oleszak, E. L., Chang, J. R., Friedman, H., Katsetos, C. D., & Platsoucas, C. D. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.174-207.2004 · Cited by 308
Mediation of Cardioprotection by Transforming Growth Factor-β
Lefer, A. M., Tsao, P., Aoki, N., & Palladino, M. A. (1990) · Science · doi:10.1126/science.2164258 · Cited by 299
Self-citationAsher, A. L., Mulé, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., & Rosenberg, S. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3227 · Cited by 281
Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60294-8 · Cited by 275
Immunoregulatory mechanisms of the eye
Streilein, J. W., Wilbanks, G. A., & Cousins, S. W. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90253-h · Cited by 157
Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.78.6.0944 · Cited by 146
The immunological consequences of injury
Ni Choileain, N., & Redmond, H. P. (2006) · The Surgeon · doi:10.1016/s1479-666x(06)80018-1 · Cited by 73
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Demidem, A., Taylor, J. R., Grammer, S. F., & Streilein, J. W. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12469761 · Cited by 50
NAGANUMA, H., SASAKI, A., SATOH, E., NAGASAKA, M., NAKANO, S., ISOE, S., TASAKA, K., & NUKUI, H. (1996) · Neurologia medico-chirurgica · doi:10.2176/nmc.36.789 · Cited by 42
MILES, D., THOMSEN, L., BALKWILL, F., THAVASU, P., & MONCADA, S. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb01087.x · Cited by 26
Metadata
- Authors
- Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1987-10-01
- Volume
- 166
- Issue
- 4
- Pages
- 991-998
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2021107622
- Cited by
- 494
- References
- 13
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.